PL2956163T3 - Kompozycje do leczenia patologicznego zwapnienia i kostnienia - Google Patents
Kompozycje do leczenia patologicznego zwapnienia i kostnieniaInfo
- Publication number
- PL2956163T3 PL2956163T3 PL14751154.7T PL14751154T PL2956163T3 PL 2956163 T3 PL2956163 T3 PL 2956163T3 PL 14751154 T PL14751154 T PL 14751154T PL 2956163 T3 PL2956163 T3 PL 2956163T3
- Authority
- PL
- Poland
- Prior art keywords
- ossification
- compositions
- treating pathological
- pathological calcification
- calcification
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764297P | 2013-02-13 | 2013-02-13 | |
| US201361904786P | 2013-11-15 | 2013-11-15 | |
| PCT/US2014/015945 WO2014126965A2 (en) | 2013-02-13 | 2014-02-12 | Compositions and methods for treating pathological calcification and ossification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2956163T3 true PL2956163T3 (pl) | 2025-04-14 |
Family
ID=51354667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14751154.7T PL2956163T3 (pl) | 2013-02-13 | 2014-02-12 | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US9744219B2 (enExample) |
| EP (2) | EP2956163B1 (enExample) |
| JP (4) | JP6894664B2 (enExample) |
| ES (1) | ES3014398T3 (enExample) |
| PL (1) | PL2956163T3 (enExample) |
| WO (1) | WO2014126965A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2956163T3 (pl) * | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| ES2899895T3 (es) * | 2014-12-19 | 2022-03-15 | Inozyme Pharma Inc | Procedimientos de tratamiento de calcificación tisular |
| JP6995627B2 (ja) * | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | 病的石灰化状態を治療するための組成物およびそれを使用する方法 |
| JP2018537093A (ja) | 2015-11-20 | 2018-12-20 | イエール ユニバーシティ | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| US11364284B2 (en) | 2016-06-16 | 2022-06-21 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
| US11390859B2 (en) | 2016-08-05 | 2022-07-19 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ， インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
| EP3790628A4 (en) * | 2018-05-08 | 2022-03-09 | Yale University | COMPOSITIONS AND METHODS FOR REDUCING THE PROGRESSION OF NEPHROLITHIASIS |
| EP3844280A4 (en) | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| BR112022024958A2 (pt) | 2020-06-09 | 2022-12-27 | Inozyme Pharma Inc | Proteínas enpp1 solúveis e usos das mesmas |
| TW202216186A (zh) * | 2020-07-02 | 2022-05-01 | 美商伊諾臻醫藥公司 | 用於治療同種異體移植物血管病變之組成物與方法 |
| CA3195071A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US6043056A (en) | 1998-11-06 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Cell surface glycoproteins |
| US7888372B2 (en) | 2001-03-23 | 2011-02-15 | National Institutes Of Health (Nih) | Compositions and methods for modulating bone mineral deposition |
| AU2002258592A1 (en) * | 2001-03-23 | 2002-11-25 | The Burnham Institute | Compositions and methods for modulating bone mineral deposition |
| EP1478772A2 (en) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US7323542B2 (en) | 2002-02-21 | 2008-01-29 | University Of Virginia Patent Foundation | Bone targeting peptides |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| AU2011362576B2 (en) | 2011-03-11 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | NPP1 fusion proteins |
| PL2956163T3 (pl) * | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| ES2899895T3 (es) * | 2014-12-19 | 2022-03-15 | Inozyme Pharma Inc | Procedimientos de tratamiento de calcificación tisular |
| JP6995627B2 (ja) | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | 病的石灰化状態を治療するための組成物およびそれを使用する方法 |
-
2014
- 2014-02-12 PL PL14751154.7T patent/PL2956163T3/pl unknown
- 2014-02-12 JP JP2015558092A patent/JP6894664B2/ja active Active
- 2014-02-12 US US14/765,514 patent/US9744219B2/en active Active
- 2014-02-12 ES ES14751154T patent/ES3014398T3/es active Active
- 2014-02-12 EP EP14751154.7A patent/EP2956163B1/en active Active
- 2014-02-12 EP EP24215211.4A patent/EP4523757A3/en active Pending
- 2014-02-12 WO PCT/US2014/015945 patent/WO2014126965A2/en not_active Ceased
-
2017
- 2017-03-22 US US15/466,401 patent/US9913881B2/en active Active
- 2017-08-08 US US15/671,287 patent/US20170333533A1/en not_active Abandoned
- 2017-08-25 US US15/686,972 patent/US10052367B2/en active Active
-
2018
- 2018-07-12 US US16/033,948 patent/US10624958B2/en active Active
-
2019
- 2019-07-24 JP JP2019135862A patent/JP6944977B2/ja active Active
-
2020
- 2020-03-09 US US16/813,315 patent/US11266722B2/en active Active
-
2021
- 2021-06-23 JP JP2021104071A patent/JP7420766B2/ja active Active
-
2022
- 2022-01-28 US US17/587,253 patent/US20220152163A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002210A patent/JP2024026704A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014126965A3 (en) | 2014-10-09 |
| US20170252414A1 (en) | 2017-09-07 |
| JP7420766B2 (ja) | 2024-01-23 |
| HK1214952A1 (en) | 2016-08-12 |
| ES3014398T3 (en) | 2025-04-22 |
| EP2956163A2 (en) | 2015-12-23 |
| JP2024026704A (ja) | 2024-02-28 |
| US10624958B2 (en) | 2020-04-21 |
| JP2021143202A (ja) | 2021-09-24 |
| JP6944977B2 (ja) | 2021-10-06 |
| US10052367B2 (en) | 2018-08-21 |
| US20170333533A1 (en) | 2017-11-23 |
| JP2016509023A (ja) | 2016-03-24 |
| US9744219B2 (en) | 2017-08-29 |
| US9913881B2 (en) | 2018-03-13 |
| EP2956163A4 (en) | 2017-03-22 |
| WO2014126965A2 (en) | 2014-08-21 |
| JP6894664B2 (ja) | 2021-06-30 |
| JP2019196392A (ja) | 2019-11-14 |
| US20150359858A1 (en) | 2015-12-17 |
| US20220152163A1 (en) | 2022-05-19 |
| EP4523757A3 (en) | 2025-07-16 |
| US11266722B2 (en) | 2022-03-08 |
| EP2956163B1 (en) | 2024-11-27 |
| US20170354719A1 (en) | 2017-12-14 |
| US20180318401A1 (en) | 2018-11-08 |
| EP4523757A2 (en) | 2025-03-19 |
| US20200237882A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2956163T3 (pl) | Kompozycje do leczenia patologicznego zwapnienia i kostnienia | |
| HUE051373T2 (hu) | Készítmények MPSI kezelésére | |
| ZA201601970B (en) | Compositions useful for treating disorders related to kit | |
| IL246023A0 (en) | Methods and preparations for the treatment of age-related conditions | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| IL241078A0 (en) | Synergistic preparations | |
| GB201420103D0 (en) | Treating particles | |
| IL239921A0 (en) | Preparations containing solutions in solid state and their use for the treatment of pain | |
| PL2792364T3 (pl) | Kompozycja do zapobiegania lub do leczenia kaca | |
| EP2989123A4 (en) | METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS | |
| IL244118A0 (en) | Compounds and methods for the treatment of chronic urticaria | |
| IL239680B (en) | Preparations and methods for polynucleotide transfection | |
| PL2968226T3 (pl) | Kompozycje oksprenololu do leczenia raka | |
| IL237483A0 (en) | Preparations for the treatment of psoriasis | |
| IL245703A0 (en) | Methods and preparations for the treatment of amyloid deposits | |
| ZA201507015B (en) | Composition for treating hemorrhoids | |
| EP2968550A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | |
| GB201302475D0 (en) | Compositions and methods for treating biofilms | |
| GB201302474D0 (en) | Compositions and methods for treating biofilms | |
| GB201302472D0 (en) | Compositions and methods for treating biofilms | |
| ZA201404930B (en) | Plant treatment composition | |
| GB201322764D0 (en) | Treating places | |
| GB201319951D0 (en) | Treating Particle | |
| AU2013903871A0 (en) | Compositions for treating skin conditions |